Background
Phase III RCT (POG 8631/CCG 923). 126 children (3–18 years) with standard-risk (M0, GTR) medulloblastoma. First major trial to demonstrate feasibility of reduced-dose CSI (23.4 Gy) with adjuvant chemotherapy as alternative to standard 36 Gy CSI. Randomized post-RT maintenance chemotherapy (CCNU + vincristine + cisplatin) vs RT alone.
Interventions and follow up
Arm A: CSI 23.4 Gy + posterior fossa boost 55.8 Gy + adjuvant chemotherapy (CCNU + vincristine + cisplatin × 8 cycles)
Arm B: CSI 36 Gy + posterior fossa boost 55.8 Gy (no chemotherapy)
Primary endpoint: EFS
mFollow up: 5.0 year
Arm B: CSI 36 Gy + posterior fossa boost 55.8 Gy (no chemotherapy)
Primary endpoint: EFS
mFollow up: 5.0 year
Results
5-yr EFS (chemo + reduced CSI): 79% vs RT alone (36 Gy) 52%, P=.006
5-yr OS: 85% (chemo arm) vs 65% (RT alone), P=.01
Neurocognitive (IQ at 5 yr): Significantly higher in 23.4 Gy arm vs 36 Gy
5-yr OS: 85% (chemo arm) vs 65% (RT alone), P=.01
Neurocognitive (IQ at 5 yr): Significantly higher in 23.4 Gy arm vs 36 Gy
Adverse events
Main adverse events: Chemotherapy arm: CCNU/vincristine/cisplatin — ototoxicity grade ≥2 in 22%, myelosuppression. RT: both arms had neurocognitive decline; 36 Gy arm worse. No treatment-related deaths.
Conclusions
Reduced-dose CSI (23.4 Gy) combined with adjuvant chemotherapy achieved superior EFS compared to standard 36 Gy CSI alone in standard-risk medulloblastoma, establishing the paradigm of combined-modality therapy with dose reduction. This trial fundamentally changed the standard of care.
Key Limitations
Key Limitations: Small sample size. Photon-based RT only. No molecular stratification. The chemotherapy regimen (CCNU/vincristine/cisplatin) causes significant late toxicity including ototoxicity and secondary malignancies. Long-term neurocognitive outcomes were not fully captured.
Clinical Context
POG 8631/CCG 923 established CSI 23.4 Gy + boost + adjuvant chemotherapy as the standard of care for average-risk medulloblastoma — a paradigm still in use today. It demonstrated that chemotherapy can compensate for lower RT doses. Modern approaches further refine RT volumes (tumor bed boost, ACNS0331) and explore molecular stratification.
References
References: Packer RJ et al, JCO 1994 (POG 8631/CCG 923)